Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
April 16, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024 01:00 ET
|
argenx SE
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first...
JAKKS Pacific, Inc. Announces First Quarter 2024 Earnings Call
April 15, 2024 23:54 ET
|
JAKKS Pacific Inc.
JAKKS Pacific, Inc. Announces First Quarter 2024 Earnings Call
Alternus Clean Energy, Inc. Reports FY 2023 Financial Results
April 15, 2024 19:56 ET
|
Alternus Clean Energy
Alternus Clean Energy, Inc. Reports FY 2023 Audited Financial Results
- Revenue up by 17.5% YoY
- Gross profit up by 25% YoY
BRP et son actionnaire principal annoncent un reclassement par voie de prise ferme
April 15, 2024 19:10 ET
|
BRP Inc.
VALCOURT, Québec, 15 avr. 2024 (GLOBE NEWSWIRE) -- BRP inc. (TSX : DOO; NASDAQ : DOOO) (« BRP » ou la « Société ») a annoncé aujourd’hui que Bain Capital Integral Investors II, L.P. (« Bain »...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of March 2024
April 15, 2024 18:30 ET
|
ArrowMark Financial Corp.
DENVER, April 15, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of March...
Agrify Corporation Reports Full-Year 2023 Earnings
April 15, 2024 17:42 ET
|
Agrify
Agrify Corporation Reports Full-Year 2023 Earnings - Company achieves first positive quarterly net income of approximately $572,000
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 15, 2024 17:20 ET
|
Aileron Therapeutics, Inc.
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of...
Mawson Infrastructure Group Inc. Announces New Board Chair
April 15, 2024 17:15 ET
|
Mawson Infrastructure Group Inc.
Mawson Infrastructure Group Inc. Announces New Board Chair
Orgenesis Provides Year End Business Update
April 15, 2024 17:07 ET
|
Orgenesis Inc.
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare...